Role of corticotropin-releasing factor and corticosterone in behavioral sensitization to ethanol

Raúl Pastor, Cheryl Reed, Paul J. Meyer, Carrie McKinnon, Andrey Ryabinin, Tamara Phillips

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Neuroadaptations underlying sensitization to drugs of abuse seem to influence compulsive drug pursuit and relapse associated with addiction. Our previous data support a role for the corticotropin-releasing factor (CRF) type-1 receptor (CRF 1) in ethanol (EtOH)-induced psychomotor sensitization. CRF 1 is endogenously activated by CRF and urocortin-1. Because genetic deletion of urocortin-1 did not affect EtOH sensitization, we hypothesized that CRF is the important ligand underlying EtOH sensitization. To test this hypothesis, we used heterozygous and homozygous knockout (KO) mice, which lack one or both copies of the gene coding for CRF, and their respective wild-type controls. EtOH sensitization was normal in heterozygous, but absent in homozygous, CRF KO mice. Corticosterone (CORT) levels were drastically reduced only in CRF KO mice. Because CRF/CRF 1 initiate EtOH-induced activation of the hypothalamic- pituitary-adrenal axis, we investigated CORT effects on EtOH sensitization. The CORT synthesis inhibitor metyrapone prevented the acquisition, but not the expression, of EtOH sensitization. Exogenous CORT administration sensitized the locomotor response to a subsequent EtOH challenge; we observed, however, that the exogenous CORT levels necessary to induce sensitization to EtOH were significantly higher than those produced by EtOH treatment. Therefore, participation of CORT seems to be necessary, but not sufficient, to explain the role of CRF/CRF 1 in the acquisition of sensitization to EtOH. Extra-hypothalamic CRF/CRF 1 mechanisms are suggested to be involved in the expression of EtOH sensitization. The present results are consistent with current theories proposing a key role for CRF and CRF 1 in drug-induced neuroplasticity, dependence, and addictive behavior.

Original languageEnglish (US)
Pages (from-to)455-463
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume341
Issue number2
DOIs
StatePublished - May 1 2012

Fingerprint

Corticotropin-Releasing Hormone
Corticosterone
Ethanol
Urocortins
Knockout Mice
Pituitary Hormone-Releasing Hormones
Addictive Behavior
Metyrapone
Neuronal Plasticity
Street Drugs
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Role of corticotropin-releasing factor and corticosterone in behavioral sensitization to ethanol. / Pastor, Raúl; Reed, Cheryl; Meyer, Paul J.; McKinnon, Carrie; Ryabinin, Andrey; Phillips, Tamara.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 341, No. 2, 01.05.2012, p. 455-463.

Research output: Contribution to journalArticle

@article{7181248444044210a3663725947b8645,
title = "Role of corticotropin-releasing factor and corticosterone in behavioral sensitization to ethanol",
abstract = "Neuroadaptations underlying sensitization to drugs of abuse seem to influence compulsive drug pursuit and relapse associated with addiction. Our previous data support a role for the corticotropin-releasing factor (CRF) type-1 receptor (CRF 1) in ethanol (EtOH)-induced psychomotor sensitization. CRF 1 is endogenously activated by CRF and urocortin-1. Because genetic deletion of urocortin-1 did not affect EtOH sensitization, we hypothesized that CRF is the important ligand underlying EtOH sensitization. To test this hypothesis, we used heterozygous and homozygous knockout (KO) mice, which lack one or both copies of the gene coding for CRF, and their respective wild-type controls. EtOH sensitization was normal in heterozygous, but absent in homozygous, CRF KO mice. Corticosterone (CORT) levels were drastically reduced only in CRF KO mice. Because CRF/CRF 1 initiate EtOH-induced activation of the hypothalamic- pituitary-adrenal axis, we investigated CORT effects on EtOH sensitization. The CORT synthesis inhibitor metyrapone prevented the acquisition, but not the expression, of EtOH sensitization. Exogenous CORT administration sensitized the locomotor response to a subsequent EtOH challenge; we observed, however, that the exogenous CORT levels necessary to induce sensitization to EtOH were significantly higher than those produced by EtOH treatment. Therefore, participation of CORT seems to be necessary, but not sufficient, to explain the role of CRF/CRF 1 in the acquisition of sensitization to EtOH. Extra-hypothalamic CRF/CRF 1 mechanisms are suggested to be involved in the expression of EtOH sensitization. The present results are consistent with current theories proposing a key role for CRF and CRF 1 in drug-induced neuroplasticity, dependence, and addictive behavior.",
author = "Ra{\'u}l Pastor and Cheryl Reed and Meyer, {Paul J.} and Carrie McKinnon and Andrey Ryabinin and Tamara Phillips",
year = "2012",
month = "5",
day = "1",
doi = "10.1124/jpet.111.190595",
language = "English (US)",
volume = "341",
pages = "455--463",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Role of corticotropin-releasing factor and corticosterone in behavioral sensitization to ethanol

AU - Pastor, Raúl

AU - Reed, Cheryl

AU - Meyer, Paul J.

AU - McKinnon, Carrie

AU - Ryabinin, Andrey

AU - Phillips, Tamara

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Neuroadaptations underlying sensitization to drugs of abuse seem to influence compulsive drug pursuit and relapse associated with addiction. Our previous data support a role for the corticotropin-releasing factor (CRF) type-1 receptor (CRF 1) in ethanol (EtOH)-induced psychomotor sensitization. CRF 1 is endogenously activated by CRF and urocortin-1. Because genetic deletion of urocortin-1 did not affect EtOH sensitization, we hypothesized that CRF is the important ligand underlying EtOH sensitization. To test this hypothesis, we used heterozygous and homozygous knockout (KO) mice, which lack one or both copies of the gene coding for CRF, and their respective wild-type controls. EtOH sensitization was normal in heterozygous, but absent in homozygous, CRF KO mice. Corticosterone (CORT) levels were drastically reduced only in CRF KO mice. Because CRF/CRF 1 initiate EtOH-induced activation of the hypothalamic- pituitary-adrenal axis, we investigated CORT effects on EtOH sensitization. The CORT synthesis inhibitor metyrapone prevented the acquisition, but not the expression, of EtOH sensitization. Exogenous CORT administration sensitized the locomotor response to a subsequent EtOH challenge; we observed, however, that the exogenous CORT levels necessary to induce sensitization to EtOH were significantly higher than those produced by EtOH treatment. Therefore, participation of CORT seems to be necessary, but not sufficient, to explain the role of CRF/CRF 1 in the acquisition of sensitization to EtOH. Extra-hypothalamic CRF/CRF 1 mechanisms are suggested to be involved in the expression of EtOH sensitization. The present results are consistent with current theories proposing a key role for CRF and CRF 1 in drug-induced neuroplasticity, dependence, and addictive behavior.

AB - Neuroadaptations underlying sensitization to drugs of abuse seem to influence compulsive drug pursuit and relapse associated with addiction. Our previous data support a role for the corticotropin-releasing factor (CRF) type-1 receptor (CRF 1) in ethanol (EtOH)-induced psychomotor sensitization. CRF 1 is endogenously activated by CRF and urocortin-1. Because genetic deletion of urocortin-1 did not affect EtOH sensitization, we hypothesized that CRF is the important ligand underlying EtOH sensitization. To test this hypothesis, we used heterozygous and homozygous knockout (KO) mice, which lack one or both copies of the gene coding for CRF, and their respective wild-type controls. EtOH sensitization was normal in heterozygous, but absent in homozygous, CRF KO mice. Corticosterone (CORT) levels were drastically reduced only in CRF KO mice. Because CRF/CRF 1 initiate EtOH-induced activation of the hypothalamic- pituitary-adrenal axis, we investigated CORT effects on EtOH sensitization. The CORT synthesis inhibitor metyrapone prevented the acquisition, but not the expression, of EtOH sensitization. Exogenous CORT administration sensitized the locomotor response to a subsequent EtOH challenge; we observed, however, that the exogenous CORT levels necessary to induce sensitization to EtOH were significantly higher than those produced by EtOH treatment. Therefore, participation of CORT seems to be necessary, but not sufficient, to explain the role of CRF/CRF 1 in the acquisition of sensitization to EtOH. Extra-hypothalamic CRF/CRF 1 mechanisms are suggested to be involved in the expression of EtOH sensitization. The present results are consistent with current theories proposing a key role for CRF and CRF 1 in drug-induced neuroplasticity, dependence, and addictive behavior.

UR - http://www.scopus.com/inward/record.url?scp=84859940325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859940325&partnerID=8YFLogxK

U2 - 10.1124/jpet.111.190595

DO - 10.1124/jpet.111.190595

M3 - Article

C2 - 22333290

AN - SCOPUS:84859940325

VL - 341

SP - 455

EP - 463

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -